Business

Avalyn Pharma announced that an oversubscribed Series C financing brought in $175 million that the company will use for continued development of AP01 inhaled pirfenidone and AP02 inhaled nintedanib for the treatment of pulmonary fibrosis.… Read more . . .

ReCode Therapeutics announced that it has raised $50 million as an extension to a Series B financing, with funds going toward clinical development of its inhaled mRNA therapies for the treatment of primary ciliary dyskinesia… Read more . . .

The Western Australian Future Health Research and Innovation Fund has awarded a A$499,241 Innovation Seed Fund grant to Virex Pharma for development of Glyxine, an inhaled antiviral nanoemulsion, for the treatment of respiratory syncytial virus. According to… Read more . . .

Virpax Pharmaceuticals announced that it has spun off a wholly-owned subsidiary called Novvae Pharmaceuticals that will develop Virpax’s over-the-counter products, starting with AnQlar antiviral nasal spray. Virpax acquired North American rights to AnQlar, which contains… Read more . . .

According to Evoke Pharma, the company has received a notice of allowance from the US Patent and Trademark Office (USPTO) for patent application No. 17/366,829 (“Nasal Formulations of Metoclopramide”). The patent will cover the composition of Evoke’s… Read more . . .

Oxford Science Enterprises and Harrington Discovery Institute at University Hospitals, together with the University of Edinburgh’s Old College Capital venture investment fund, have created a startup called AlveoGene to develop inhaled gene therapies based on… Read more . . .

According to Orexo, the United States Patent and Trademark Office (USPTO) has issued the company US patent No. 11,737,980 (“Pharmaceutical composition for drug delivery”) which provides protection for OX640 epinephrine nasal powder. Orexo notes that… Read more . . .